Mark Mossler - 14 Feb 2024 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Accounting Officer
Signature: /s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol: CCCC
Transactions as of: 14 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 10 Apr 2024, 16:16:41 UTC
Previous filing: 19 Sep 2023
Next filing: 18 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Award	$0	+18,290	+1219%	$0.000000	19,790	14 Feb 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Stock Option (Right to Buy)	Award	$0	+27,430		$0.000000	27,430	14 Feb 2024	Common Stock	27,430	$7.31	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025.
F2	Includes 1,500 shares of Common Stock that were inadvertently omitted from the Form 3 filed by the Reporting Person on September 19, 2023.
F3	The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024.